Centralized administration is critical for efficient project management, coordination, and execution. Core A (Administrative Core) will provide all the logistic, scientific, managerial, financial, and biostatistics support to facilitate and to coordinate the studies described in this Consortium. The Administrative Core will ensure that all the Projects and Cores function optimally and adhere to the timelines described in the individual sections of this grant. The Administrative Core will establish a Scientific Leadership Committee as the primary decision making committee for this Consortium, organize conference calls every two weeks and regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, manage subcontracts, and coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials. This detailed administration and management structure will ensure that all the studies remain focused on the overall objective to evaluate the early events of acute mucosal SIV/SHIV infection and the capacity of vaccines to impact these events. To accomplish these goals, we propose the following five Specific Aims: 1. To coordinate communications, interactions, and operations among investigators, Projects, and Cores to facilitate the overall progress and goals of this Consortium; 2. To ensure and to maintain regulatory compliance; 3. To provide detailed financial oversight and management; 4. To coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials;and 5. To provide biostatistics support for all Projects and Cores.
A major roadblock is our current lack of understanding of the earliest events following mucosal HIV-1 exposure and the potential vaccine-elicited immune responses that might be able to impact these events. This consortium brings together leaders in the nonhuman primate and HIV-1 vaccine fields to address these questions. To accomplish these goals, a centralized Administrative Core is proposed to coordinate the efforts of the projects and cores.
|Stephenson, Kathryn E; Neubauer, George H; Reimer, Ulf et al. (2015) Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods 416:105-23|
|Barouch, Dan H; Picker, Louis J (2014) Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12:765-71|
|Dugast, Anne-Sophie; Chan, Ying; Hoffner, Michelle et al. (2014) Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 9:e97229|
|Balandya, Emmanuel; Miller, Andrew D; Beck, Matthew et al. (2014) Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys. J Virol 88:3756-65|
|Barouch, Dan H; Michael, Nelson L (2014) Accelerating HIV-1 Vaccine Efficacy Trials. Cell 159:969-72|
|Li, Qingsheng; Zeng, Ming; Duan, Lijie et al. (2014) Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 193:3113-25|
|Whitney, James B; Hill, Alison L; Sanisetty, Srisowmya et al. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74-7|
|Teigler, Jeffrey E; Phogat, Sanjay; Franchini, Genoveffa et al. (2014) The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 88:1809-14|
|Shang, Liang; Smith, Anthony J; Duan, Lijie et al. (2014) NK cell responses to simian immunodeficiency virus vaginal exposure in naive and vaccinated rhesus macaques. J Immunol 193:277-84|
|Barouch, Dan H; Deeks, Steven G (2014) Immunologic strategies for HIV-1 remission and eradication. Science 345:169-74|
Showing the most recent 10 out of 20 publications